Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 40 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia is related to leukemia, acute lymphoblastic and leukemia, chronic myeloid, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Leukemia is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and Increased HDAC inhibitor resistance

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 72 Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1413)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 34.5 ABL1 FLT3 PBX1 RUNX1
2 leukemia, chronic myeloid 34.5 ABL1 FLT3 MCL1 RUNX1
3 acute promyelocytic leukemia 34.3 FLT3 NPM1 PML RUNX1 ZBTB16
4 childhood leukemia 34.3 ABL1 PBX1 PTPN11 RUNX1
5 juvenile myelomonocytic leukemia 34.2 FLT3 PTPN11 RAF1 RUNX1
6 acute myeloblastic leukemia without maturation 34.1 FLT3 NPM1
7 acute myeloblastic leukemia with maturation 34.1 FLT3 NPM1
8 acute lymphocytic leukemia 34.0 MCL1 RUNX1 TAL2
9 leukemia, acute myeloid 34.0 ABL1 FLT3 MCL1 MLF1 NPM1 PML
10 cytogenetically normal acute myeloid leukemia 33.9 FLT3 NPM1
11 myeloid leukemia 33.8 ABL1 FLT3 LIF MCL1 MLF1 NPM1
12 leukemia, acute lymphoblastic 3 33.7 ABL1 FLT3 HLF PBX1 RUNX1
13 aleukemic leukemia cutis 33.7 FLT3 NPM1 RUNX1
14 lymphoblastic leukemia 33.6 ABL1 FLT3 HLF LYL1 PBX1 RUNX1
15 b-cell adult acute lymphocytic leukemia 33.6 ABL1 PBX1
16 precursor t-cell acute lymphoblastic leukemia 33.5 ABL1 FLT3 LYL1 TCL1A
17 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.3 FLT3 RUNX1 RUNX1T1
18 lymphoid leukemia 33.1 RUNX1 RUNX1T1
19 myelodysplastic syndrome 32.8 ABL1 FLT3 MLF1 NPM1 PTPN11 RUNX1
20 alk-positive anaplastic large cell lymphoma 29.6 MCL1 NPM1
21 hematologic cancer 29.5 ABL1 FLT3 NPM1 PTPN11 RUNX1 RUNX1T1
22 leukemia, chronic lymphocytic 12.4
23 hairy cell leukemia 12.3
24 megakaryocytic leukemia 12.3
25 acute leukemia 12.3
26 leukemia, acute monocytic 12.2
27 adult t-cell leukemia 12.2
28 mast-cell leukemia 12.2
29 t-cell prolymphocytic leukemia 12.2
30 atypical chronic myeloid leukemia 12.2
31 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 12.2
32 prolymphocytic leukemia 12.2
33 chronic myelomonocytic leukemia 12.2
34 monocytic leukemia 12.2
35 pdgfrb-associated chronic eosinophilic leukemia 12.2
36 acute monoblastic leukemia 12.2
37 plasma cell leukemia 12.2
38 acute lymphoblastic leukemia, childhood 12.2
39 large granular lymphocyte leukemia 12.2
40 chronic leukemia 12.1
41 t-cell large granular lymphocyte leukemia 12.1
42 chronic neutrophilic leukemia 12.1
43 chronic eosinophilic leukemia 12.1
44 core binding factor acute myeloid leukemia 12.1
45 b cell prolymphocytic leukemia 12.1
46 leukemia, chronic lymphocytic 2 12.1
47 human t-cell leukemia virus type 1 12.1
48 subleukemic leukemia 12.1
49 acute basophilic leukemia 12.0
50 subacute leukemia 12.0

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.1 MCL1 MLF1 PBX1 RUNX1 RUNX1T1 ZBTB16
2 Increased HDAC inhibitor resistance GR00115-A-0 8.96 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 ABL1 FLI1 FLT3 LIF LIFR LYL1
2 cellular MP:0005384 10.36 ABL1 ABL2 FLI1 FLT3 LIF MCL1
3 growth/size/body region MP:0005378 10.32 FLT3 LIF LIFR NPM1 PBX1 PTPN11
4 immune system MP:0005387 10.3 ABL1 FLI1 FLT3 LIF LIFR LYL1
5 embryo MP:0005380 10.28 ABL1 ABL2 FLI1 LIF LIFR MCL1
6 mortality/aging MP:0010768 10.27 FLI1 FLT3 HLF LIF LIFR MCL1
7 cardiovascular system MP:0005385 10.26 RAF1 RUNX1 RUNX1T1 ABL1 ABL2 FLI1
8 endocrine/exocrine gland MP:0005379 10.26 ABL1 FLI1 FLT3 LIF LIFR MCL1
9 homeostasis/metabolism MP:0005376 10.26 TAL2 ZBTB16 ABL1 ABL2 FLT3 HLF
10 liver/biliary system MP:0005370 10.06 PBX1 PTPN11 RAF1 RUNX1 ABL1 FLI1
11 integument MP:0010771 10.03 RUNX1T1 LIF MCL1 NPM1 PBX1 PTPN11
12 nervous system MP:0003631 10.03 FLI1 HLF LIF LIFR NPM1 PBX1
13 neoplasm MP:0002006 9.92 FLI1 FLT3 NPM1 PML PTPN11 RAF1
14 normal MP:0002873 9.76 ABL1 MCL1 PBX1 PML PTPN11 RAF1
15 reproductive system MP:0005389 9.61 ABL2 LIF LIFR MCL1 PBX1 PTPN11
16 skeleton MP:0005390 9.28 ABL1 FLT3 LIF LIFR PBX1 PTPN11

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 30)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 17 45 OFATUMUMAB GlaxoSmithKline October 2009
3
Blincyto 17 45 BLINATUMOMAB Amgen December 2014
4
Bosulif 17 45 BOSUTINIB MONOHYDRATE Pfizer September 2012
5
Busulfex 17 45 BUSULFAN Orphan Medical February 1999
6
Campath 17 45 ALEMTUZUMAB Berlex Laboratories May 2001
7
Clolar 17 45 CLOFARABINE Genzyme December, 2004
8
Elitek 17 45 RASBURICASE sanofi-aventis October 2009
9
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
10
Erwinaze 17 45 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
11
Gazyva 17 45 OBINUTUZUMAB Genentech October of 2013
12
Gleevec 17 45 IMATINIB MESYLATE Novartis May 2001
13
Iclusig 17 45 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
14
Imbruvica 17 45 IBRUTINIB Pharmacyclics November of 2013/February 2014
15
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
16
Leukine 17 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
17
Lynparza 17 45 OLAPARIB AstraZeneca December 2014
18
Marqibo 17 45 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 17 45 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 17 45 FILGRASTIM Amgen Approval April 1998
21
Pomalyst 17 45 POMALIDOMIDE Celgene February 2013
22
Revlimid 17 45 LENALIDOMIDE Celgene June 2013
23
Rituxan 17 45 RITUXIMAB Biogen IDEC, Genentech November 1997
24
Sprycel 17 45 DASATINIB Bristol-Myers Squibb June 2006
25
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
26
Synribo 17 45 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
27
Tasigna 17 45 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
28
Treanda 17 45 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
29
Trisenox 17 45 ARSENIC TRIOXIDE Cell Therapeutics September 2000
30
Zydelig 17 45 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 924)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
8
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
10
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53910-25-1 439693 40926
11
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
12
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
14
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
16
Asparaginase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
17
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
18
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
21
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
22
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
23
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
24
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
25
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 4291-63-8 20279
26
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
27
Teniposide Approved Phase 4,Phase 3,Phase 2 29767-20-2 34698
28
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
29
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
30
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
31
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 6918365 151165
32
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090
33
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
34
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
35
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
36
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
37
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
39
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
40
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
41
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
42
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
43
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 145941-26-0
44
Granisetron Approved, Investigational Phase 4,Phase 2 109889-09-0 3510
45
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
46
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
47
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
48
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
49 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
50
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show top 50) (show all 6090)

# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
3 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
10 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
11 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
12 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
13 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
14 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
15 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
16 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
17 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
18 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
19 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
20 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
21 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
22 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
23 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
24 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
25 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
26 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
27 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
28 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
29 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
30 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
31 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
32 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
33 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
34 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
35 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
36 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
37 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
38 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
39 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
40 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
41 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
42 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
43 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
44 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
45 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
46 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
47 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4 chemotherapy
48 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
49 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
50 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 28

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

38
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Breast

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 28825)
# Title Authors Year
1
Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing. ( 29238890 )
2018
2
<i>PDGFRB</i> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. ( 29434033 )
2018
3
Somatic<i>STAT3</i>mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. ( 29217783 )
2018
4
Chronic neutrophilic leukemia: new science and new diagnostic criteria. ( 29440636 )
2018
5
Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda. ( 29307444 )
2018
6
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. ( 29449543 )
2018
7
A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. ( 29437791 )
2018
8
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
9
High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. ( 29032147 )
2018
10
Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities. ( 29105850 )
2018
11
Targeting the bone marrow microenvironment in acute leukemia. ( 29431560 )
2018
12
Immunosuppressive monocytes (CD14<sup>+</sup>/HLA-DR<sup>low/-</sup>) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy. ( 29429058 )
2018
13
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
14
Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia. ( 29423023 )
2018
15
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
16
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. ( 29148847 )
2018
17
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
18
Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. ( 29441205 )
2018
19
Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. ( 29435190 )
2018
20
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
21
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. ( 29090524 )
2018
22
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
23
A Controlled Trial of Sheng-Yu-Tang for Post-Hematopoietic Stem Cell Transplantation Leukemia Patients: A Proposed Protocol and Insights From a Preliminary Pilot Study. ( 29431027 )
2018
24
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
25
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
26
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
27
Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. ( 29416774 )
2018
28
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
29
A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. ( 29411267 )
2018
30
Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series. ( 29407318 )
2018
31
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. ( 29449683 )
2018
32
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. ( 29232592 )
2018
33
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN<sup>TM</sup>analyzers in routine laboratory practice. ( 29310473 )
2018
34
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
35
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
36
Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. ( 29449437 )
2018
37
MicroRNA expression and activity in T-cell acute lymphoblastic leukemia. ( 29435192 )
2018
38
Late effects awareness website for pediatric survivors of acute lymphocytic leukemia. ( 29451924 )
2018
39
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. ( 29404721 )
2018
40
Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort: A comparison with controls from the French population. ( 29351982 )
2018
41
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. ( 28776669 )
2018
42
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. ( 29407588 )
2018
43
Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. ( 29382244 )
2018
44
Diagnostic Dilemma in Ambiguous Lineage Acute Leukemia: A Case Report. ( 29398827 )
2018
45
Lymphoplasmacytoid cytology in plasma cell leukemia. ( 29027254 )
2018
46
A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of I^-thalassemia major: A case report. ( 29435306 )
2018
47
Adult T cell leukemia/lymphoma with different pathological features in each tumor site. ( 29427186 )
2018
48
Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. ( 29435279 )
2018
49
Vaccine-associated paralytic poliomyelitis in a patient with acute lymphocytic leukemia. ( 29322435 )
2018
50
Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. ( 29424258 )
2018